PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an... Read More

PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43 r d Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on Wednesday, January 15, 2025. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be available for two weeks... Read More

Expresses Conviction in Pacira's IP and Belief that Shares are Significantly Undervalued Urges Pacira to Immediately Commence Stock Tender Offer with Cash on Hand MIAMI , Dec. 11, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 4.14% of the outstanding shares of Common Stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the... Read More

PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with... Read More

First in new family of EXPAREL patents Expands EXPAREL intellectual property and provides protection into 2044 PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the ‘940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The ‘940... Read More

PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201 (enekinragene inzadenovec), provided sustained improvements in knee pain, stiffness, and function to 104 weeks following local... Read More

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 19 th at 3:00PM GMT (10:00AM ET). 36 th Annual Piper Sandler Healthcare Conference on Tuesday, December 3 rd at 1:00PM ET. Live audio of the events can be... Read More

Conference call today at 4:30 p.m. ET PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc . (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights Total revenues of $168.6 million Net product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and... Read More

Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera° via product-specific reimbursement codes PARSIPPANY, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NSDQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform... Read More

PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please... Read More

TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseeing all aspects of the company’s financial operations. “We are delighted to welcome Shawn as our new Chief Financial Officer and... Read More

TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq... Read More

New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent product-specific Healthcare... Read More

Poster to be presented at ACR Convergence annual meeting TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentation of new data in support of its gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data will be presented at the American College of Rheumatology’s... Read More

Believes Pacira's Cash Balance of $400 million , Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI , Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of Pacira Biosciences (NYSE: PCRX ) urging the Board to accelerate and... Read More

TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the granting of inducement awards on September 4, 2024 to 17 new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In... Read More

TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid. “We remain steadfast in our belief in the strength and validity of our... Read More

Conference call today at 4:30 p.m. ET TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2024. Second Quarter 2024 Financial Highlights Total revenues of $178.0 million Net product sales of $136.9 million for EXPAREL, $30.7... Read More

TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register... Read More

Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment Rule implements the NOPAIN Act, signed into law as part of the Consolidated Appropriations Act of 2023 TAMPA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NSDQ: PCRX), the industry leader in its... Read More

TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare Conference at 11:00 AM ET on Thursday, June 6, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be... Read More

TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also granted the initial purchasers of the notes an option to... Read More

TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends... Read More

Conference call today at 4:30 p.m. ET TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024. First Quarter 2024 Financial Highlights Total revenues of $167.1 million Net product sales of $132.4 million for EXPAREL, $25.8 million... Read More

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also... Read More

TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. To participate in the conference call, dial 1-800-715-9871 and provide the passcode 6363041. International... Read More

TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be... Read More

PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis Designation supported by encouraging preliminary data from 72-patient Phase 1 study 52-Week Data Accepted for Presentation at OARSI 2024 and 104-week data to be submitted for presentation later this year TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its... Read More

TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26 th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be... Read More

Record revenues of $675 million in 2023 Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million EXPAREL surpasses the 14 million patient mark Conference call today at 8:30 a.m. ET TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for... Read More

TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session... Read More

Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator Significantly greater proportion of opioid-free patients receiving EXPAREL TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. , (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the publication of its... Read More

TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. , (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc. Effective January 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and... Read More

High Demand for Participation in Pickleball's Big Game on Feb. 9 in Las Vegas Leads to Tournament's Expansion to 24 Teams and Signing of New Sponsors LAS VEGAS , Feb. 1, 2024 /PRNewswire/ -- Paradise PB Events and G.O.A.T. Paddle , the high performance pickleball company created by and for top players and those who want to compete like them, today announced the expansion of G.O.A.T. Bowl I tournament play in Las Vegas to 24... Read More

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023, compared with $666.8 million for the year ended December 31, 2022. “We enter 2024 with a strong financial and operational... Read More

TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be available for two weeks... Read More

Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization Paul J. Hastings Named Chair of the Board Dave Stack to Remain in Advisory Role through August 2025 TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health... Read More

EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX),... Read More

TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 14 th at 11:00AM GMT (6:00AM ET). 35 th Annual Piper Sandler Healthcare Conference on Tuesday, November 28 th at 2:00PM ET. Live audio of the events can be... Read More

New ASA initiatives to advance education and innovation for the anesthesia community PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 Conference call today at 8:30 a.m. ET TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported... Read More

TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday November 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register... Read More

SCHAUMBERG, Ill. and TAMPA, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) today announced Pacira BioSciences, Inc. (Nasdaq: PCRX) has joined ASA’s Industry Supporter Program to support the Society’s more than 56,000 physician anesthesiologist members to improve patient care and reduce reliance on opioids for the treatment of postsurgical or chronic pain. “We are delighted to... Read More

Enhances diversity and expertise in key areas including scientific, commercial, and financial TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors... Read More

SCHAUMBURG, Ill. and TAMPA, Fla., Oct. 02, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. (Nasdaq: PCRX), today announced a new grant of $2.5 million, by Pacira to the ASA Charitable Foundation, to advance the medical specialty of anesthesiology and pain medicine; facilitate best-in-class clinician education; and improve patient care. “ASA has long been driven by a... Read More

David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that David (“Dave”) Stack will retire from his role as Chairman and Chief Executive Officer. To ensure a... Read More

TAMPA, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25 th Annual Global Investment Conference. The pre-recorded audio of the virtual event can be accessed beginning Monday, September 11 th at 7:00AM ET by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the... Read More

Conference call today at 8:30 a.m. ET TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023. Second Quarter 2023 Financial Highlights Total revenues of $169.5 million Net product sales of $135.1 million for EXPAREL, $29.3... Read More

TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please... Read More

TAMPA, Fla., May 31, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 Jefferies Healthcare Conference at 9:30 AM ET on Wednesday, June 7, 2023 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be available for... Read More

TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference at 3:05 PM ET on Tuesday, May 16, 2023 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be... Read More

EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year Conference call today at 8:30 a.m. ET TAMPA, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2023. First Quarter 2023... Read More

TAMPA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 3, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register... Read More

TAMPA, Fla. and IRVING, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. , the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and the Invited Celebrity Classic, an officially sanctioned PGA TOUR Champions event, today announced a partnership naming Pacira’s pain management device, iovera° , as The Official Non-Opioid Pain Management Partner of the... Read More

TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Officer. Mr. Young will be responsible for oversight of all manufacturing activities across the Pacira product portfolio including supply chain... Read More

TAMPA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference at 10:15 AM ET on Wednesday, April 19, 2023. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be... Read More

Term Loan A Carries Significantly Lower Interest Rate Meaningfully Improves Debt Leverage Ratio and Reaffirms Outlook for Growth TAMPA, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, announced the repayment on March 31, 2023 of $287.5 million in Term Loan B debt, which represented all... Read More

TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include both single-dose sciatic nerve block in the... Read More

TAMPA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that the United States Court of Appeals for the Third Circuit affirmed the District Court’s dismissal of the Company’s suit against the American Society of Anesthesiologists (ASA) and various other defendants. This decision was predicated on the court’s view that the findings in the Anesthesiology articles represented... Read More

TAMPA, Fla., March 22, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that after serving as an independent director for nine years, Yvonne Greenstreet, MBChB, is retiring from the company’s Board of Directors effective March 31, 2023. Dr. Greenstreet is currently serving as Chief Executive... Read More

TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be available... Read More

Record revenues of $667 million in 2022 Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million EXPAREL surpasses the 12 million patient mark Conference call today at 8:30 a.m. E T TAMPA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results... Read More

DAYTONA BEACH, Fla. and TAMPA, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. , (Nasdaq: PCRX), a company committed to non-opioid pain management and regenerative health solutions, and the Ladies Professional Golf Association (LPGA) announced today a multi-year sponsorship that makes Pacira’s iovera ° — a handheld medical device that provides non-medicated pain control by applying cold therapy to a specific... Read More

TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before the open of the U.S. markets on Tuesday, February 28, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session... Read More

TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent. The company’s 2022 revenue includes net product sales of EXPAREL ®... Read More

TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM EST) on Monday, January 9, 2023. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com . A replay of the webcast will also be available for two weeks following the... Read More